Last Updated: November 16, 2026

Details for Patent: 8,993,640

« Back to Dashboard


Summary for Patent: 8,993,640
Title:2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Abstract:The present invention relates generally to the compound:
Inventor(s):Eric Anderson, Xiaofeng Liu, Andrea Decker
Assignee: Solvias AG , Reata Pharmaceuticals Holdings LLC
Application Number:US13/869,833
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

US Patent 8,993,640: Omaveloxolone Claims, Patent Scope, Exclusivity and Generic Risk

US Patent 8,993,640 is a core Reata Pharmaceuticals patent covering omaveloxolone, now marketed by Biogen as Skyclarys. The patent has four principal claim groups: the active compound, solid-state forms and solvates, pharmaceutical compositions, and methods for treating inflammation- or oxidative-stress-related diseases. Its broadest commercial relevance is the compound claim and the composition claim. The polymorph claims provide narrower manufacturing and formulation protection, while the method claims cover several non-Friedreich ataxia indications, including radiation-induced dermatitis and mucositis.

The patent was granted on March 31, 2015. Its ordinary US patent term is expected to run into approximately 2030, subject to the controlling USPTO term calculation, terminal disclaimers, and any patent-term adjustment. Skyclarys received FDA approval on February 28, 2023, for Friedreich's ataxia in adults and adolescents aged 16 years and older. The approval created separate regulatory exclusivity that is distinct from the patent term.

What drug does US Patent 8,993,640 protect?

US 8,993,640 protects omaveloxolone, also known as RTA 408. The compound is an activator of nuclear factor erythroid 2-related factor 2, or Nrf2, and is intended to regulate antioxidant and anti-inflammatory pathways.

The plaintext claim set supplied omits the chemical structure drawings. The patent's claim architecture, disease indications, and solid-state disclosures identify the claimed compound as omaveloxolone and its pharmaceutically acceptable salts.

Patent field Data
US patent 8,993,640
Grant date March 31, 2015
Original patent owner Reata Pharmaceuticals, Inc.
Current commercial owner Biogen Inc., following Biogen's acquisition of Reata
Active ingredient Omaveloxolone, RTA 408
Product Skyclarys
FDA approval February 28, 2023
Approved indication Friedreich's ataxia in patients aged 16 years and older
Primary protection types Compound, polymorph, solvate, composition, method of treatment
Expected ordinary patent-term horizon Approximately 2030
FDA regulatory exclusivity Orphan-drug exclusivity through approximately February 2030, subject to the approved indication and statutory rules

Sources: US Patent No. 8,993,640; FDA, Skyclarys prescribing information; FDA Orange Book.

What are the independent claims in US 8,993,640?

The patent has five commercially important independent claims or independent claim categories.

Claim 1: Omaveloxolone and pharmaceutically acceptable salts

Claim 1 covers the compound shown in the patent's formula and pharmaceutically acceptable salts. This is the principal composition-of-matter claim.

A valid infringement case under claim 1 would generally focus on whether a competing product contains omaveloxolone or a salt within the claimed structural definition. The claim does not depend on a particular dosage form, excipient, indication, manufacturing process, or crystal form.

This claim has the broadest blocking effect because it can reach:

  • Tablets containing omaveloxolone.
  • Omaveloxolone supplied as a free compound or pharmaceutically acceptable salt.
  • Products using a different excipient system.
  • Products used for a different therapeutic indication.
  • Products using a different polymorph, unless the accused form falls outside the compound claim's scope.

A generic manufacturer cannot avoid a compound claim merely by changing tablet excipients or labeling the product for a different disease. It would need to avoid the claimed chemical structure, challenge validity, or obtain a license.

Claims 2-18: Polymorphic forms and solvates

Claims 2 through 18 cover specific solid-state forms of the claimed compound. These claims are narrower than claim 1 and rely on analytical characteristics, including:

  • Powder X-ray diffraction, or XRPD, peaks.
  • A halo peak near 14° 2θ.
  • A shoulder peak near 8° 2θ.
  • Differential scanning calorimetry, or DSC, endotherms.
  • Glass-transition temperatures.
  • Solvate-specific diffraction patterns.
  • An acetonitrile hemisolvate with a Tg of approximately 196°C.

The solid-state claim groups are as follows:

Claims Covered form Defining characteristics
2-7 Polymorphic form XRPD halo near 14° 2θ; optional shoulder near 8°; Tg or DSC event around 150-155°C
8-9 Solvate Significant XRPD peaks near 5.6, 7.0, 10.6, 12.7 and 14.6° 2θ
10-11 Solvate Peaks near 7.0, 7.8, 8.6, 11.9, 13.9, 14.2 and 16.0° 2θ
12-16 Acetonitrile hemisolvate Peaks near 7.5, 11.4, 15.6 and 16.6° 2θ; Tg or DSC event near 196°C
17-18 Solvate Peaks near 6.8, 9.3, 9.5, 10.5, 13.6 and 15.6° 2θ

These claims are important for manufacturing control. A commercial product may use a particular crystalline form because it has better stability, filtration, drying, dissolution, or storage characteristics. A generic developer can attempt to manufacture a different form, but it must establish that the alternative does not reproduce the claimed XRPD, DSC, Tg, or solvate characteristics.

Claim 19: Pharmaceutical composition

Claim 19 covers a pharmaceutical composition containing the claim 1 compound as the active ingredient and a pharmaceutically acceptable carrier.

This claim is broader than a claim limited to the marketed Skyclarys tablet because it does not recite:

  • A specific dose.
  • A particular tablet weight.
  • A defined excipient list.
  • A specific dissolution profile.
  • A particular polymorph.
  • A specific method of manufacture.

The phrase "active ingredient consisting of a compound of claim 1" may limit the claim to the identified active compound rather than a combination product. The carrier limitation is conventional, but it still provides a product claim directed to pharmaceutical preparations containing omaveloxolone.

Claims 20-23: Therapeutic methods

Claim 20 covers treatment of conditions associated with inflammation or oxidative stress using the composition of claim 19. The listed conditions include:

  • Prostate cancer.
  • Dermatitis.
  • Sepsis.
  • Pulmonary inflammation.
  • Pulmonary fibrosis.
  • Chronic obstructive pulmonary disease.
  • Asthma.
  • Mucositis.
  • Ocular inflammation.

Claim 21 narrows dermatitis to radiation-induced dermatitis. Claim 22 addresses radiation- or chemotherapy-induced mucositis. Claim 23 covers reducing the duration or severity of radiation-induced oral mucositis or dermatitis by administering the composition before and/or after acute radiation treatment.

These claims are method-of-use claims, not product claims. They may be relevant to a company developing omaveloxolone for oncology supportive care, radiation injury, pulmonary disease, or inflammatory disorders. They do not necessarily block a generic seeking approval solely for Friedreich's ataxia if the relevant indication is carved out and the Orange Book-listed use does not create an infringement issue.

How strong is the compound claim compared with the polymorph claims?

The compound claim is materially stronger from a commercial blocking perspective than the solid-state claims.

Issue Claim 1 compound Claims 2-18 solid-state forms
Scope Broad chemical identity Specific crystal or solvate forms
Design-around potential Low if the product must use omaveloxolone Higher through alternative forms or amorphous material
Dependence on analytical testing Limited High
Relevance to formulation manufacture Direct Strong where the marketed form is used
Vulnerability to claim construction disputes Structural identity XRPD peak positions, solvation state, measurement conditions
Generic litigation importance Primary barrier Secondary or reinforcing barrier
Potential validity issues Written description, enablement, structure Indefiniteness, anticipation, reproducibility, polymorph characterization

The solid-state claims could be difficult to enforce if the patent does not clearly establish the identity, stoichiometry, or reproducibility of each solvate. XRPD peak positions are also subject to instrument conditions, sample preparation, preferred orientation, humidity, and measurement error. Claims tied to a figure may raise claim-construction questions about whether the figure defines an exact pattern or merely illustrates a representative pattern.

What formulations are protected by US 8,993,640?

The patent protects pharmaceutical compositions containing the claimed compound and a pharmaceutically acceptable carrier. It does not, based on the supplied claims, require the commercial Skyclarys excipient system or a particular tablet design.

The formulation scope can therefore reach:

  • Immediate-release solid oral dosage forms.
  • Tablets using conventional diluents, binders, lubricants, and disintegrants.
  • Capsules.
  • Formulations containing a covered polymorph or solvate.
  • Products using a pharmaceutically acceptable salt.

The claims supplied do not expressly recite:

  • A fixed 50-mg or 100-mg dose.
  • A twice-daily dosing regimen.
  • A specific particle-size distribution.
  • A controlled-release profile.
  • A particular dissolution specification.
  • A specific excipient combination.

Those features may be addressed in later patent families or regulatory product specifications, but they are not limitations apparent from claim 19.

When does omaveloxolone lose exclusivity?

Omaveloxolone has separate patent and FDA exclusivity layers.

Patent exclusivity

US 8,993,640 was granted in 2015 and has an ordinary term extending approximately to 2030. The exact expiration date depends on the patent's earliest effective nonprovisional or PCT filing date and any patent-term adjustment.

A patent expiration date does not automatically permit unrestricted generic entry if later, independently valid patents cover the approved product, a formulation, a method of use, or a manufacturing process.

Orphan-drug exclusivity

FDA approved Skyclarys for Friedreich's ataxia on February 28, 2023. Orphan-drug exclusivity generally runs for seven years from approval, placing the principal regulatory exclusivity endpoint in approximately February 2030. Orphan exclusivity blocks FDA approval of the same drug for the same orphan indication, subject to statutory exceptions. It does not prevent all off-label use or approval for a different indication.

New chemical entity exclusivity

If Skyclarys received five-year new chemical entity exclusivity, that period would run approximately through February 2028. NCE exclusivity restricts submission or approval timing for certain abbreviated applications, but it is separate from both the patent term and orphan exclusivity.

Protection Approximate endpoint Practical effect
NCE exclusivity February 2028 Limits certain ANDA submissions or approvals during the statutory period
Orphan exclusivity for Friedreich's ataxia February 2030 Blocks approval of the same drug for the same orphan indication
US 8,993,640 patent Approximately 2030 Potentially blocks products practicing the compound, composition, or covered methods
Later patent families Potentially beyond 2030 May extend formulation, use, or manufacturing barriers

What is the Orange Book status of US 8,993,640?

US 8,993,640 is associated with the Skyclarys patent estate and is relevant to FDA-listed patent analysis for omaveloxolone. The Orange Book must be reviewed for the exact patent number, use code, and listed expiration date because FDA listing information can distinguish between:

  • Drug-substance patents.
  • Drug-product patents.
  • Method-of-use patents.
  • Patents applying only to specific indications.

An Orange Book listing does not establish patent validity or infringement. It triggers the certification framework for an ANDA applicant and gives the patent holder an opportunity to bring a Hatch-Waxman action after a Paragraph IV notice.

Which companies are challenging omaveloxolone patents?

No publicly established Paragraph IV litigation or final settlement involving a generic omaveloxolone challenger is identified in the supplied record. The principal commercial actors are:

Company Role
Reata Pharmaceuticals Originator and original patent owner
Biogen Current commercial owner following acquisition of Reata
Generic manufacturers Potential ANDA applicants after applicable regulatory and patent barriers
FDA NDA approval, Orange Book listing, and ANDA certification authority

An ANDA applicant would likely face a Paragraph IV certification against relevant listed patents or a Paragraph III certification deferring approval until patent expiry. A section viii statement could be used to carve out a patented method of use if the generic label excludes the protected indication.

What Paragraph IV risks exist?

The main Paragraph IV theories would likely target different claim groups separately.

Claim 1 invalidity or noninfringement

A challenger could argue that:

  • The claimed structure lacks adequate written description.
  • The compound was anticipated by earlier NRF2 activators.
  • The claim is obvious based on prior chemical series.
  • The generic product does not contain the claimed compound or salt.

For a true omaveloxolone product, noninfringement of claim 1 would generally be difficult if the structural formula covers the active ingredient as identified.

Polymorph claim challenges

The polymorph claims may be challenged on:

  • Anticipation by prior solid-state disclosures.
  • Obviousness based on routine crystallization screening.
  • Indefiniteness of "about" peak positions.
  • Unclear distinction between polymorph, amorphous form, and solvate.
  • Lack of reproducibility or enablement.
  • Failure to identify the solvent content or stoichiometry of a solvate.

A generic manufacturer may also attempt to use a form that is not among the claimed XRPD patterns.

Method-of-use carve-outs

Claims 20-23 are more susceptible to label-based design-around than claim 1. A generic product could seek approval for Friedreich's ataxia while omitting radiation-induced dermatitis, mucositis, and other patented uses, assuming the relevant FDA labeling and marketing conduct support a noninfringement position.

Does omaveloxolone face biosimilar risk?

No. Omaveloxolone is a small-molecule drug, not a biologic. A competitor would use the ANDA pathway for a chemically equivalent generic, not the biosimilar pathway under the Public Health Service Act.

The relevant competitive risks are:

  • ANDA submission after regulatory exclusivity restrictions expire.
  • Paragraph IV patent litigation.
  • Formulation and polymorph design-arounds.
  • Off-label competition from other antioxidant or anti-inflammatory therapies.
  • New products targeting Friedreich's ataxia through different mechanisms.

What licensing deals affect the patent estate?

Reata developed omaveloxolone and commercialized the program before its acquisition by Biogen. Reata also had a broader strategic collaboration with AbbVie involving certain Nrf2 activator programs. That collaboration was terminated, with rights returning to Reata. Biogen's acquisition transferred control of Reata's commercial assets and patent portfolio to Biogen.

The Reata-AbbVie history is relevant to chain-of-title review, but it does not by itself establish that AbbVie retains rights to US 8,993,640. Current ownership, recorded assignments, security interests, and licensing restrictions should be assessed through USPTO assignment records and the relevant transaction documents.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Scenario Timing Risk profile
No early challenge After applicable patent and exclusivity expirations Lowest litigation risk; latest entry
Paragraph IV challenge After ANDA eligibility and before patent expiry High litigation and launch-at-risk exposure
Section viii carve-out After regulatory barriers, with patented uses excluded Reduces method-of-use risk but does not avoid compound claims

A product that contains omaveloxolone remains exposed to the compound and composition claims even if it uses a different crystal form. A polymorph design-around therefore may not create a complete pathway around claim 1.

How does this patent compare with later omaveloxolone patents?

US 8,993,640 is best understood as an early, foundational patent. Its value comes from the combination of a compound claim and supporting solid-state and method claims.

Later patents in the omaveloxolone estate may provide additional protection for:

  • Friedreich's ataxia treatment.
  • Dose and administration regimens.
  • Specific formulations.
  • Manufacturing processes.
  • Additional crystalline forms.
  • Commercial product characteristics.

The earlier patent is more important for chemical identity. Later patents may be more important after the 2030 compound-patent horizon if they have valid terms extending beyond that date. A full freedom-to-operate review should therefore map the complete US family, Orange Book entries, continuations, divisionals, and terminal disclaimers rather than rely on US 8,993,640 alone.

Key Takeaways

  • US 8,993,640 is a foundational omaveloxolone patent associated with Skyclarys.
  • Claim 1 is the central commercial barrier because it covers the active compound and pharmaceutically acceptable salts.
  • Claims 2-18 protect selected polymorphs, solvates, and an acetonitrile hemisolvate using XRPD, Tg, and DSC characteristics.
  • Claim 19 covers pharmaceutical compositions containing omaveloxolone.
  • Claims 20-23 cover treatment of inflammatory, oxidative-stress, radiation, and mucositis conditions.
  • The patent's ordinary term is expected to extend approximately to 2030.
  • Skyclarys has separate NCE and orphan-drug exclusivity, with orphan protection for Friedreich's ataxia expected to run approximately through February 2030.
  • Omaveloxolone is a small molecule and faces generic, not biosimilar, competition.
  • A polymorph design-around may avoid claims 2-18 but would not necessarily avoid claim 1 or claim 19.
  • The strongest generic challenge points are likely solid-state claim construction, polymorph validity, method-of-use carve-outs, and any later Orange Book-listed patents.

FAQs

Is US 8,993,640 a composition-of-matter patent for omaveloxolone?

Yes. Claim 1 covers the claimed omaveloxolone structure and pharmaceutically acceptable salts, making it the principal composition-of-matter claim.

Can a generic use a different omaveloxolone polymorph?

Possibly, but a different polymorph would not by itself avoid the compound claim or the pharmaceutical-composition claim. The alternative form would need to avoid the specific solid-state claims and any later polymorph patents.

Does US 8,993,640 cover Skyclarys dosing?

The supplied claims do not recite a specific Skyclarys dose or dosing schedule. Dose-specific protection may reside in other patent families.

Can a generic obtain approval for Friedreich's ataxia while carving out radiation-induced mucositis?

Potentially. Claims 21-23 are method-of-use claims directed to radiation-related conditions, so a section viii carve-out may be relevant if the approved labeling and commercial conduct exclude those uses.

Is Biogen the current owner of the patent?

Biogen acquired Reata Pharmaceuticals and its commercial assets, including the omaveloxolone program. The definitive legal owner and any encumbrances should be confirmed against the latest USPTO assignment record.

References

  1. Biogen Inc. (2023). Skyclarys (omaveloxolone) prescribing information. U.S. Food and Drug Administration.

  2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  3. United States Patent and Trademark Office. (2015). U.S. Patent No. 8,993,640: Compounds and methods for treating oxidative stress-related diseases. Washington, DC: U.S. Department of Commerce.

  4. Biogen Inc. (2023). Biogen completes acquisition of Reata Pharmaceuticals. Company transaction announcement.

  5. Reata Pharmaceuticals, Inc. (2020). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,993,640

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Us SKYCLARYS omaveloxolone CAPSULE;ORAL 216718-001 Feb 28, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,993,640

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2841445 ⤷  Start Trial CA 2024 00015 Denmark ⤷  Start Trial
European Patent Office 2841445 ⤷  Start Trial PA2024511 Lithuania ⤷  Start Trial
European Patent Office 2841445 ⤷  Start Trial LUC00340 Luxembourg ⤷  Start Trial
European Patent Office 2841445 ⤷  Start Trial 301276 Netherlands ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.